CTI BioPharma Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CTI BioPharma Corp. (CTIC), a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers, primarily operates in the United States. The company offers VONJO (pacritinib), an oral kinase inhibitor specific to JAK2, FLT3, IRAK1, and CSF1R, approved for treating adult patients with intermediate- or high-risk myelofibrosis who have thrombocytopenia; it previously marketed PIXUVRI (pixantrone) in Europe for relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Founded in 1991 and headquartered in Seattle, Washington, CTI BioPharma maintains license and collaboration agreements with Teva Pharmaceutical Industries Ltd., S*BIO Pte Ltd., and others, targeting patients with hematologic malignancies. In a major strategic development, Swedish Orphan Biovitrum AB (Sobi) acquired CTI BioPharma for $1.7 billion in May 2023, with the transaction completing on June 26, 2023, after which CTIC was delisted from Nasdaq and now operates as a wholly owned subsidiary of Sobi, enhancing the parent's hematology portfolio with VONJO's complementary profile to products like Doptelet.
Sobi completes acquisition of CTI BioPharma Corp.
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
CTI BioPharma skyrockets on acquisition by Sobi
Why Shares of CTI BioPharma Are Soaring Wednesday
Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi
U.S. stock futures climb as inflation continues to cool
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
Sobi to Acquire CTI BioPharma
Sobi to Acquire CTI BioPharma
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)